(a) CD45+CD3+TCRγδ+IL-17A+ γδT17 cell numbers in tumour-infiltrating lymphocytes (TIL) following B16 melanoma challenge (n=5/time point). (b) γδT17 cell numbers in TIL d7 post-challenge with B16 melanoma in wild type (WT) (n=12) and Ccr6−/− mice (n=13). (c) γδT17 cell numbers in central nervous system (CNS) at experimental autoimmune encephalomyelitis (EAE) onset in WT (n=7) and Ccr6−/− mice (n=6). (d) γδT17 cell numbers in TIL and inguinal lymph nodes (iLN) d7 post-challenge with B16 melanoma in WT (n=15 (TIL), 9 (iLN)), Ccr2−/− (n=13 (TIL), 10 (iLN)) and Ccr2−/−Ccr6−/− mice (n=9 (TIL), 5 (iLN)). (e) ELISA for CCL2 in tumour supernatant from WT mice challenged with B16 melanoma (n=5/time point). (f) γδT17 cell numbers in CNS and iLN at EAE onset in WT (n=14), Ccr2−/− (n=13) and Ccr2−/−Ccr6−/− mice (n=12). (g) γδT17 cell numbers in CNS at peak disease in WT (n=6), Ccr2−/− (n=5) and Ccr2−/−Ccr6−/− mice (n=6). (h) ELISA for CCL2 in CNS of WT mice with EAE (n=4/time point). (i) Ly5.1 mice (n=4) at d5 post-challenge with B16 melanoma were transferred i.v. with in vitro-expanded γδT17 cells from Ccr2−/− (CD45.2+) and F1 (CD45.1+CD45.2+) mice. Ccr2−/−:F1 total, Vγ4 and Vγ6 γδT17 cell ratios in spleen and tumours were normalized to input ratio. Vγ4 and Vγ6 γδT17 cells were determined by CD3bright gating. Representative flow cytometry of CD45.2+ γδT17 cells at d7 or input. (j) Ly5.1 mice (n=7) at EAE onset were transferred with F1 and Ccr2−/− γδT17 cells as in (i). Twenty-four hours later, ratios of Ccr2−/−:F1 γδT17 cells in spleen, blood and CNS were normalized to input. Representative flow cytometry of CD45.2+ γδT17 cells 24 h later or input. See also . Mean±s.e.m. (a,c,e,i) Representative of two experiments. (b,d,f,j) Pooled from two experiments. (b,c) Unpaired two-tailed Student's t-test, (d,f–g,j) one-way ANOVA with Bonferroni's multiple comparisons test (paired in j)), (i) paired two-tailed Student's t-test. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.